Illingworth Research are currently working with Bridge BioResearch on an exciting phase II study in patients with Diabetic Foot Ulcers. This study is looking at the healing properties of a compound used for decades in another therapeutic area.
We are pleased to announce that Professor Andrew JM Boulton, Professor of Medicine, University of Manchester, and Consultant Physician, Manchester Royal Infirmary, has agreed to undertake the role of Chief Investigator, and Professor Keith Harding, Professor of Rehabilitation Medicine (Wound Healing) and Head of the Department of Dermatology and Wound Healing, Cardiff University Hospital, has accepted to undertake a role as Principle Investigator.
With a number of sites across the UK, this proof of concept study will soon be underway. MHRA approval has been granted and we are awaiting MREC approval.
Professor Harding states, “To be part of the clinical trial team in this project is of great scientific importance for all aspects in wound healing”. Professor Boulton adds, “When it comes to our focus area, the diabetic foot ulcer, then there is a huge amount of unmet need, both in order to optimize treatment, but also to improve the quality of life of the patients”.